The injectable medication is the first glucagon-like peptide-1 receptor agonist — a drug class that includes Ozempic, Mounjaro and Trulicity — to be approved for serious heart problems in obese and overweight adults.
The FDA’s approval label hooks on that Wegovy (semaglutide) should be used alongside a reduced calorie diet and increased physical activity.
About 70% of U.S. adults are obese or overweight, which the FDA said are “serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.”
In a phase 3 trial — which included more than 17,000 obese and overweight adults and lasted five years — the medication reduced major adverse cardiovascular events by 20% and quelled heart failure-related symptoms.
Read more here about how Wegovy compares to other GLP-1s.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
